InsuletPODD
PODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 71
13% more capital invested
Capital invested by funds: $14.3B [Q2] → $16.2B (+$1.9B) [Q3]
3% more funds holding
Funds holding: 589 [Q2] → 609 (+20) [Q3]
5% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 232
1.48% less ownership
Funds ownership: 101.44% [Q2] → 99.96% (-1.48%) [Q3]
29% less call options, than puts
Call options by funds: $163M | Put options by funds: $228M
75% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 2 (-6) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$234
12%
downside
Avg. target
$292
10%
upside
High target
$330
24%
upside
9 analyst ratings
8 positive
89%
1 neutral
11%
0 negative
0%
JP Morgan Robbie Marcus 48% 1-year accuracy 10 / 21 met price target | 24%upside $330 | Overweight Maintained | 12 Dec 2024 |
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target | 16%upside $310 | Buy Maintained | 11 Dec 2024 |
Wells Fargo Lawrence Biegelsen 0% 1-year accuracy 0 / 2 met price target | 14%upside $305 | Overweight Maintained | 11 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 14%upside $304 | Buy Maintained | 9 Dec 2024 |
Barclays Matt Miksic 61% 1-year accuracy 22 / 36 met price target | 12%downside $234 | Equal-Weight Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 7 articles about PODD published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 week ago
RMD or PODD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
Zacks Investment Research
1 week ago
Should You Continue to Retain Insulet Stock in Your Portfolio Now?
PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.
Positive
Reuters
2 weeks ago
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.
Neutral
Business Wire
2 weeks ago
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
4 weeks ago
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Positive
Seeking Alpha
1 month ago
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth.
Neutral
Business Wire
1 month ago
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. “We are excited to announce that Omnipod 5, the only AID system.
Neutral
Business Wire
1 month ago
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd An.
Charts implemented using Lightweight Charts™